Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin

ConclusionThe dUr level before and during administration of 5-FU and arfolitixorin was predictive for toxicity and early clinical response and could be a potential surrogate marker for thymidylate synthase inhibition in patients with mCRC.Trial registrationNCT02244632, first posted on ClinicalTrials.gov on September 19, 2014
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research